High intratumoural galectin-1 expression predicts adverse outcome in ALK− ALCL and CD30+ PTCL-NOS

MLA

Knud Bendix, et al. High Intratumoural Galectin-1 Expression Predicts Adverse Outcome in ALK− ALCL and CD30+ PTCL-NOS. Feb. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....56f5e786286e583d143b666280a9c84a&authtype=sso&custid=ns315887.

APA

Knud Bendix, Gabriel A. Rabinovich, Torben Steiniche, Martin Bjerregård Pedersen, Johanne Marie Holst, Francesco d’Amore, Trine Lindhardt Plesner, Peter Nørgaard, Stephen Hamilton-Dutoit, Maja Ludvigsen, & Michael Boe Møller. (2020). High intratumoural galectin-1 expression predicts adverse outcome in ALK− ALCL and CD30+ PTCL-NOS.

Chicago

Knud Bendix, Gabriel A. Rabinovich, Torben Steiniche, Martin Bjerregård Pedersen, Johanne Marie Holst, Francesco d’Amore, Trine Lindhardt Plesner, et al. 2020. “High Intratumoural Galectin-1 Expression Predicts Adverse Outcome in ALK− ALCL and CD30+ PTCL-NOS,” February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....56f5e786286e583d143b666280a9c84a&authtype=sso&custid=ns315887.